NPS Pharmaceuticals Issues New Stock

NPS Pharmaceuticals will be in excess of $80 million richer in the very near future if its new public common stock offering is successful. The company has priced the previously announced, 6-million-share issue at $14.53 per share. All told, this should yield gross proceeds of just over $87 million.

The offering's underwriters, meanwhile, have been granted a 30-day option to buy up to an additional 900,000 shares to cover over-allotments, if any.

NPS Pharmaceuticals plans to use the proceeds of the issue for investments, product development, future licensing opportunities, and "general corporate purposes."

JPMorgan Chase's J.P. Morgan Securities and Morgan Stanley are the joint book-running managers of the offering, which is expected to close "on or about" May 24.

The article NPS Pharmaceuticals Issues New Stock originally appeared on Fool.com.

Fool contributor Eric Volkman has no position in any stocks mentioned. The Motley Fool owns shares of JPMorgan Chase. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.